Melanoma
News and reporting on melanoma.
Castle Biosciences Q4 Revenues up 31 Percent
The company saw a boost in testing volume in the fourth quarter, but not across all its assays, while full-year revenues grew 51 percent.
Metastatic Melanoma Study Finds Immunotherapy Resistance Mutations in Immune-Linked Genes
Researchers identified acquired resistance mutations in metastatic melanoma, including alterations influencing innate immunity via changes to a protein transport complex.
The firm is developing prognostic cancer tests targeting "master driver" genes that control cancer-related biological pathways.
Castle Biosciences Q3 Revenues up 39 Percent
The company saw growth across its melanoma, squamous cell carcinoma, Barrett's esophagus, and pharmacogenomics tests.
Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.
Aug 30, 2024
DermTech Sells Assets, Becomes Private Company
Apr 17, 2024
DermTech Receives Delisting Warning From Nasdaq
Oct 31, 2023